Loxo Oncology (acquired)
E133655
Loxo Oncology (acquired) is a biotechnology company focused on developing targeted cancer therapies, particularly for tumors driven by specific genetic alterations.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Loxo Oncology (acquired) canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T1168586 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Loxo Oncology (acquired) Context triple: [Eli Lilly and Company, hasSubsidiary, Loxo Oncology (acquired)]
-
A.
Genentech
Genentech is a pioneering American biotechnology company known for developing groundbreaking therapies and being one of the first firms to apply genetic engineering to medicine.
-
B.
Lonza
Lonza is a global Swiss-based life sciences company specializing in pharmaceutical, biotech, and nutrition products and services, particularly in contract development and manufacturing.
-
C.
Ionis Pharmaceuticals
Ionis Pharmaceuticals is a biotechnology company specializing in the discovery and development of RNA-targeted therapeutics using antisense technology.
-
D.
Eisai
Eisai is a Japanese pharmaceutical company known for developing treatments in neurology and oncology, including Alzheimer’s disease therapies.
-
E.
AstraZeneca
AstraZeneca is a global biopharmaceutical company known for researching, developing, and manufacturing prescription medicines across areas such as oncology, cardiovascular, respiratory, and immunology.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Loxo Oncology (acquired) Target entity description: Loxo Oncology (acquired) is a biotechnology company focused on developing targeted cancer therapies, particularly for tumors driven by specific genetic alterations.
-
A.
Genentech
Genentech is a pioneering American biotechnology company known for developing groundbreaking therapies and being one of the first firms to apply genetic engineering to medicine.
-
B.
Lonza
Lonza is a global Swiss-based life sciences company specializing in pharmaceutical, biotech, and nutrition products and services, particularly in contract development and manufacturing.
-
C.
Ionis Pharmaceuticals
Ionis Pharmaceuticals is a biotechnology company specializing in the discovery and development of RNA-targeted therapeutics using antisense technology.
-
D.
Eisai
Eisai is a Japanese pharmaceutical company known for developing treatments in neurology and oncology, including Alzheimer’s disease therapies.
-
E.
AstraZeneca
AstraZeneca is a global biopharmaceutical company known for researching, developing, and manufacturing prescription medicines across areas such as oncology, cardiovascular, respiratory, and immunology.
- F. None of above. chosen
Statements (47)
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Loxo Oncology (acquired) Description of subject: Loxo Oncology (acquired) is a biotechnology company focused on developing targeted cancer therapies, particularly for tumors driven by specific genetic alterations.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.